← Leaderboards
Branden S Moriarity
University Of Minnesota
$9,306,595
Attributed
$11,744,139
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,744,139 · 12
By mechanism
R01$5,714,228 · 2
P01$2,696,715 · 2
R21$1,203,812 · 3
P50$1,187,998 · 1
R56$380,000 · 1
R03$306,208 · 2
Top collaborators
- Pamela J Skinner5 shared
- Beau Richard Webber3 shared
- R Scott Mcivor1 shared
- Theresa M Reineke1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Jeffrey S Miller$32,066,338
- Gabrielle Matilde Robbins$162,965
- Beau Richard Webber$2,853,539
- Alptekin Aksan$2,180,539
- Martin Felices$2,733,593
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCrispr/Cas TechnologyKnock-OutEngineeringSiteGenesT-LymphocyteIn VivoGenome EngineeringKnock-InRecombinant Adeno-Associated Virus (Raav)Cell TherapyIn VitroReagentAffectImmunotherapyMouse ModelSuccessAntigensChimeric Antigen ReceptorGraft Vs Host DiseaseNovel TherapeuticsBaseGenetic
Grant awards (32)
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2025 · AI
Project 3$548,644
P01 · FY2025 · CA · contact PI
In vivo and ex vivo gene editing for Artemis-deficient SCID$420,771
R21 · FY2025 · AI
Bespoke Micellar Nanoparticles (MNPs) for In Vivo Delivery of Digital Base Editor Treatments for Primary Immunodeficiency Disease$380,000
R56 · FY2025 · AI
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells$227,374
P50 · FY2025 · CA · contact PI
Genome Engineering Shared Resource$166,905
P30 · FY2025 · CA · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2024 · AI
Project 3$521,211
P01 · FY2024 · CA · contact PI
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies$387,500
R01 · FY2024 · AI · contact PI
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells$218,432
P50 · FY2024 · CA · contact PI
Genome Engineering Shared Resource$88,273
P30 · FY2024 · CA · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2023 · AI
Project 3$539,108
P01 · FY2023 · CA · contact PI
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies$387,500
R01 · FY2023 · AI · contact PI
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells$232,427
P50 · FY2023 · CA · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2022 · AI
Project 3$539,108
P01 · FY2022 · CA · contact PI
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies$387,500
R01 · FY2022 · AI · contact PI
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells$247,077
P50 · FY2022 · CA · contact PI
Activated NK CAR Cells to Cure HIV$766,149
R01 · FY2021 · AI
Project 3$548,644
P01 · FY2021 · CA · contact PI
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies$386,667
R01 · FY2021 · AI · contact PI
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells$262,688
P50 · FY2021 · CA · contact PI
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies$385,000
R01 · FY2020 · AI · contact PI
Engineered Systems for Conditional and Temporal Gene Manipulation in Primary Lymphohematopoietic Cells$77,000
R03 · FY2020 · AI · contact PI
Genetically Modified Natural Killer Cells for Cancer Immunotherapy$194,940
R21 · FY2019 · CA · contact PI
Engineered Systems for Conditional and Temporal Gene Manipulation in Primary Lymphohematopoietic Cells$77,000
R03 · FY2019 · AI · contact PI
Optimizing Gene Editing in Primary Human B Cells for Therapy and Research$191,875
R21 · FY2018 · AI · contact PI
Genetically Modified Natural Killer Cells for Cancer Immunotherapy$167,476
R21 · FY2018 · CA · contact PI
Optimizing Gene Editing in Primary Human B Cells for Therapy and Research$228,750
R21 · FY2017 · AI · contact PI
Multiplex 'Conditional' Mice for Rapid and Affordable Pre-clinical Testing$76,208
R03 · FY2017 · CA · contact PI
Multiplex 'Conditional' Mice for Rapid and Affordable Pre-clinical Testing$76,000
R03 · FY2016 · CA · contact PI